1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. Middle East and Africa Cancer Vaccines Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. Middle East and Africa Cancer Vaccines Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. Middle East and Africa Cancer Vaccines Market Regional Analysis
6.2 Middle East and Africa Cancer Vaccines Market Revenue 2017-2027 (US$ Million)
6.3 Middle East and Africa Cancer Vaccines Market Forecast Analysis
7. Middle East and Africa Cancer Vaccines Market Analysis – by Technology
7.1 Dendritic Cells Cancer Vaccines
- 7.1.1 Overview
- 7.1.2 Dendritic Cells Cancer Vaccines: Middle East and Africa Cancer Vaccines Market – Revenue and Forecast, 2017-2027 (US$ Million)
7.2 Recombinant Cancer Vaccines
- 7.2.1 Overview
- 7.2.2 Recombinant Cancer Vaccines: Middle East and Africa Cancer Vaccines Market – Revenue and Forecast, 2017-2027 (US$ Million)
7.3 Antigen Cancer Vaccines
- 7.3.1 Overview
- 7.3.2 Antigen Cancer Vaccines: Middle East and Africa Cancer Vaccines Market – Revenue and Forecast, 2017-2027 (US$ Million)
7.4 Whole Cell Cancer Vaccines
- 7.4.1 Overview
- 7.4.2 Whole Cell Cancer Vaccines: Middle East and Africa Cancer Vaccines Market – Revenue and Forecast, 2017-2027 (US$ Million)
7.5 Viral Vector Cancer Vaccines
- 7.5.1 Overview
- 7.5.2 Viral Vector Cancer Vaccines: Middle East and Africa Cancer Vaccines Market – Revenue and Forecast, 2017-2027 (US$ Million)
8. Middle East and Africa Cancer Vaccines Market Analysis – by Type
8.1 Preventive Cancer Vaccines
- 8.1.1 Overview
- 8.1.2 Preventive Cancer Vaccines: Middle East and Africa Cancer Vaccines Market – Revenue and Forecast, 2017-2027 (US$ Million)
8.2 Therapeutic Cancer Vaccines
- 8.2.1 Overview
- 8.2.2 Therapeutic Cancer Vaccines: Middle East and Africa Cancer Vaccines Market – Revenue and Forecast, 2017-2027 (US$ Million)
9. Middle East and Africa Cancer Vaccines Market Analysis – by Indication
9.1 Cervical Cancer
- 9.1.1 Overview
- 9.1.2 Cervical Cancer: Middle East and Africa Cancer Vaccines Market – Revenue and Forecast, 2017-2027 (US$ Million)
9.2 Prostate Cancer
- 9.2.1 Overview
- 9.2.2 Prostate Cancer: Middle East and Africa Cancer Vaccines Market – Revenue and Forecast, 2017-2027 (US$ Million)
9.3 Other Indications
- 9.3.1 Overview
- 9.3.2 Other Indications: Middle East and Africa Cancer Vaccines Market – Revenue and Forecast, 2017-2027 (US$ Million)
10. Middle East and Africa Cancer Vaccines Market Analysis – by End User
10.1 Pediatrics
- 10.1.1 Overview
- 10.1.2 Pediatrics: Middle East and Africa Cancer Vaccines Market – Revenue and Forecast, 2017-2027 (US$ Million)
10.2 Adults
- 10.2.1 Overview
- 10.2.2 Adults: Middle East and Africa Cancer Vaccines Market – Revenue and Forecast, 2017-2027 (US$ Million)
11. Middle East and Africa Cancer Vaccines Market – Middle East and Africa Analysis
11.1 Overview
11.2 Middle East and Africa
- 11.2.1 Middle East and Africa Cancer Vaccines Market Breakdown, by Key
Country, 2020 and 2027 (%)
- 11.2.1.1 Middle East and Africa Cancer Vaccines Market – Revenue and
Forecast Analysis – by Country
- 11.2.1.1 South Africa:
Middle East and Africa Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
- 11.2.1.1.1 South Africa: Middle East and Africa Cancer Vaccines Market Breakdown, by Technology
- 11.2.1.1.2 South Africa: Middle East and Africa Cancer Vaccines Market Breakdown, by Type
- 11.2.1.1.3 South Africa: Middle East and Africa Cancer Vaccines Market Breakdown, by Indication
- 11.2.1.1.4 South Africa: Middle East and Africa Cancer Vaccines Market Breakdown, by End User
- 11.2.1.2 Saudi Arabia:
Middle East and Africa Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
- 11.2.1.2.1 Saudi Arabia: Middle East and Africa Cancer Vaccines Market Breakdown, by Technology
- 11.2.1.2.2 Saudi Arabia: Middle East and Africa Cancer Vaccines Market Breakdown, by Type
- 11.2.1.2.3 Saudi Arabia: Middle East and Africa Cancer Vaccines Market Breakdown, by Indication
- 11.2.1.2.4 Saudi Arabia: Middle East and Africa Cancer Vaccines Market Breakdown, by End User
- 11.2.1.3 UAE:
Middle East and Africa Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
- 11.2.1.3.1 UAE: Middle East and Africa Cancer Vaccines Market Breakdown, by Technology
- 11.2.1.3.2 UAE: Middle East and Africa Cancer Vaccines Market Breakdown, by Type
- 11.2.1.3.3 UAE: Middle East and Africa Cancer Vaccines Market Breakdown, by Indication
- 11.2.1.3.4 UAE: Middle East and Africa Cancer Vaccines Market Breakdown, by End User
- 11.2.1.4 Rest of Middle East and Africa:
Middle East and Africa Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
- 11.2.1.4.1 Rest of Middle East and Africa: Middle East and Africa Cancer Vaccines Market Breakdown, by Technology
- 11.2.1.4.2 Rest of Middle East and Africa: Middle East and Africa Cancer Vaccines Market Breakdown, by Type
- 11.2.1.4.3 Rest of Middle East and Africa: Middle East and Africa Cancer Vaccines Market Breakdown, by Indication
- 11.2.1.4.4 Rest of Middle East and Africa: Middle East and Africa Cancer Vaccines Market Breakdown, by End User
12. Competitive Landscape
12.1 Heat Map Analysis
12.2 Company Positioning and Concentration
13. Industry Landscape
13.1 Overview
13.2 Market Initiative
13.3 Partnerships and Collaborations
13.4 Other Developments
14. Company Profiles
14.1 AstraZeneca
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 GlaxoSmithKline plc.
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 Aduro Biotech Inc
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 Pfizer Inc.
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 Sanofi
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 Bristol-Myers Squibb
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 Moderna, Inc.
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 OncBioMune Pharmaceuticals Inc.
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 MaxiVAX
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments
14.10 Nouscom
- 14.10.1 Key Facts
- 14.10.2 Business Description
- 14.10.3 Products and Services
- 14.10.4 Financial Overview
- 14.10.5 SWOT Analysis
- 14.10.6 Key Developments
15. Appendix
15.1 About Business Market Insights
15.2 List of Abbreviations